GlassScriptPhysician profile
William G Grubb
NPI 1093721532
$11,327.80
in general payments reported to CMS, 2019-2025
59 companies · $1,769 in 2025
The $1,769 reported for 2025 was more than what 88% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,521 · 2020: $1,156 · 2021: $1,475 · 2022: $1,930 · 2023: $2,082 · 2024: $1,395 · 2025: $1,769.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,959 · Education: $287.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,958.95 |
| Education | $287.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,142.87 | 2019-2025 | Krystexxa, Tavneos, Repatha |
| Mallinckrodt Hospital Products INC. | $1,034.85 | 2020-2025 | Acthar, Terlivaz |
| Astrazeneca Pharmaceuticals LP | $1,016.32 | 2019-2025 | Farxiga, Lokelma |
| Otsuka America Pharmaceutical, INC. | $942.57 | 2020-2025 | Jynarque, Voyxact |
| Travere Therapeutics, INC. | $726.03 | 2022-2025 | Filspari |
| Opko Pharmaceuticals, LLC | $714.29 | 2019-2023 | Rayaldee |
| Vifor Pharma, INC. | $575.92 | 2019-2023 | Veltassa |
| Ardelyx, INC. | $487.12 | 2024-2025 | Xphozah 30 Mg, Ibsrela |
| Horizon Therapeutics Plc | $460.65 | 2021-2023 | Krystexxa |
| Novartis Pharmaceuticals Corporation | $410.18 | 2020-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $345.07 | 2021-2025 | |
| Fresenius USA Marketing, INC. | $311.45 | 2019-2024 | Velphoro |
| Calliditas Therapeutics US INC. | $211.24 | 2022-2025 | Tarpeyo |
| Amarin Pharma, INC. | $207.89 | 2020-2021 | |
| Mallinckrodt Enterprises LLC | $205.42 | 2019 |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Grubb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.